Literature DB >> 6288944

Malignant mixed tumour of the liver and its response to adriamycin.

J W Leung, J Ho, K C Lam.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288944      PMCID: PMC1438583          DOI: 10.1177/014107688207500913

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  12 in total

1.  Right hepatolobectomy for primary mesenchymoma of the liver.

Authors:  W S LORIMER
Journal:  Ann Surg       Date:  1955-02       Impact factor: 12.969

2.  Liver tumour of mixed type.

Authors:  A W WILLIAMS
Journal:  Br J Surg       Date:  1953-07       Impact factor: 6.939

3.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

4.  Response of alpha-fetoprotein to chemotherapy in patients with hepatomas.

Authors:  Y Matsumoto; T Suzuki; H Ono; A Nakase; I Honjo
Journal:  Cancer       Date:  1974-11       Impact factor: 6.860

5.  Hepatoblastoma in the adult.

Authors:  R Carter
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

6.  Malignant mixed tumor of the liver: report of a case and a review of the literature.

Authors:  I Watanabe; M Kasai; T Watanuki; S Amano
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1975-06

7.  Histologic prognostic indicators in hepatocellular carcinoma.

Authors:  C L Lai; P C Wu; K C Lam; D Todd
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

8.  Serum alpha-foetoprotein in hepatocellular carcinoma--value in diagnosis, and prognosis.

Authors:  R Williams; W M Melia; P J Johnson
Journal:  Ann Acad Med Singap       Date:  1980-04       Impact factor: 2.473

9.  A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States.

Authors:  C L Vogel; A C Bayley; R J Brooker; P P Anthony; J L Ziegler
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

10.  Induction of remission in hepatocellular carcinoma with doxorubicin.

Authors:  P J Johnson; R Williams; H Thomas; S Sherlock; I M Murray-Lyon
Journal:  Lancet       Date:  1978-05-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.